Phase 3 N=102 Compare the Clinical Efficacy of Prototype Toothpastes
Dental Plaque
Primary: Plaque Index — 0.91; 0.84; 1.77 Units on a scale — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=65 CELLO - CLiRpath® Excimer Laser System to Enlarge Lumen Openings
Peripheral Artery Disease
Primary: Laser Success — 34.7 percent reduction — p=0.001
Phase 3 N=1,524 Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo
Hypertension
Primary: Change in Sitting Diastolic Blood Pressure (DBP) From Baseline to the End of the Study (From Baseline to 8 Weeks). — -3.3; -9.3; -7.7; -13.9 mm Hg
Phase 3 N=169 Effects of Colesevelam HCl, Rosiglitazone, Sitagliptin on Control of Blood Glucose and Lipids in Type 2 Diabetes Patients Whose Blood Glucose Isn't Completely Controlled With Metformin
Type 2 Diabetes · Hyperlipidemia
Primary: Mean Percentage of Change in HbA1c From Week 0(Baseline) to Week 16 Endpoint — -0.31; -0.65; -0.56 % change HbA1c — p=0.0234
Phase 3 N=58 An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Treatment-emergent Antibody Status (Maximum Titer Level Experienced) — 15; 0; 0; 0 Participants
Phase 3 N=971 Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
Essential Hypertension
Primary: Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16 — -11.16; -9.13; -8.10; -5.66 mm Hg — p=<0.0001
Phase 3 N=45 Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
Mucopolysaccharidosis I · Hurler's Syndrome · Hurler-Scheie Syndrome
Primary: Change From Baseline to Week 182 in Percent Predicted Forced Vital Capacity (FVC) — 51.0; 48.4; 47.7; 47.2 percent predicted FVC
Phase 3 N=71 Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
Kidney Failure, Acute
Primary: Number of Participants Who Had AKI (Acute Kidney Injury) — 3; 10 participants
Phase 3 N=139 Efficacy Study of a Standardized Pollen Extract Preparation (Cernilton) to Treat Inflammatory Chronic Prostatitis-Chronic Pelvic Pain Syndrome (CP-CPPS)
Chronic Prostatitis · Chronic Pelvic Pain Syndrome
Primary: Symptomatic Improvement in the Pain Domain of National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) — 47; 33 participants — p=<0.05
Phase 3 N=54 A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Primary: Change in Mean 24-hour Heart Rate From Baseline to Endpoint — 74.83; 74.47; 2.14; -0.71 beats per minute — p=0.1585
Phase 3 N=217 Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD
ADHD
Primary: Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint — -18.8; -8.8 scores on a scale…
Phase 3 N=626 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)
Chronic Hepatitis C · Cirrhosis
Primary: Time to Observation of the First Clinical Event Experienced by a Subject — 3; 2; 5; 5 Participants — p=0.1439
Phase 3 N=547 Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
Diabetes Mellitus
Primary: Nominal Change From Baseline in Percent Atheroma Volume — 40.592; 40.016; -0.161; 0.725 Percent volume — p=0.002
Phase 3 N=576 A Study to Investigate the Efficacy and Safety of Different Doses of Losartan Potassium (MK0954-011)
Hypertension
Primary: Mean Change From Baseline in Trough Supine Diastolic Blood Pressure (SuDBP) at Week 8 — -5.6; -7.9; -6.8; -10.1 mm Hg
Phase 3 N=618 A Study to Assess the Cholesterol Lowering Effect of an Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Patients With High Cholesterol and With High Cardiovascular Risk (0653A-809)(COMPLETED)
Hypercholesterolemia
Primary: Percent Change in Low Density Lipoprotein-Cholesterol (LDL-C) at Study Endpoint After Six Weeks of Treatment — -27.66; -16.94 percent change from baseline — p=<=0.001